Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Northwestern University
Beth Israel Deaconess Medical Center
Gilead Sciences
Actuate Therapeutics Inc.
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
City of Hope Medical Center
Merck Sharp & Dohme LLC
AstraZeneca
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
AstraZeneca
Pfizer
Merck Sharp & Dohme LLC
Charite University, Berlin, Germany
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
FBD Biologics Limited
Sun Yat-sen University
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Queen Mary University of London
Alliance for Clinical Trials in Oncology
Washington University School of Medicine
Washington University School of Medicine
Suzhou Transcenta Therapeutics Co., Ltd.
University Health Network, Toronto
Chinese PLA General Hospital
Abramson Cancer Center at Penn Medicine
Sun Yat-sen University
Merck Sharp & Dohme LLC
University of Southern California
Thomas Jefferson University
Gilead Sciences
Gilead Sciences
Merck Sharp & Dohme LLC
Medical College of Wisconsin
Verastem, Inc.
Virginia Commonwealth University
City of Hope Medical Center
Australasian Gastro-Intestinal Trials Group
HonorHealth Research Institute
University of Chicago
Peking University Hospital of Stomatology
City of Hope Medical Center